- Home
- COGT vs GLRE Comparison
COGT vs GLRE Comparison
Compare COGT & GLRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COGT
- GLRE
- Stock Information
- Founded
- COGT 2014
- GLRE 2004
- Country
- COGT United States
- GLRE Cayman Islands
- Employees
- COGT N/A
- GLRE N/A
- Industry
- COGT Biotechnology: Pharmaceutical Preparations
- GLRE Property-Casualty Insurers
- Sector
- COGT Health Care
- GLRE Finance
- Exchange
- COGT Nasdaq
- GLRE Nasdaq
- Market Cap
- COGT 555.6M
- GLRE 466.5M
- IPO Year
- COGT 2018
- GLRE 2007
- Fundamental
- Price
- COGT $5.44
- GLRE $14.44
- Analyst Decision
- COGT Buy
- GLRE
- Analyst Count
- COGT 6
- GLRE 0
- Target Price
- COGT $15.20
- GLRE N/A
- AVG Volume (30 Days)
- COGT 1.2M
- GLRE 95.2K
- Earning Date
- COGT 05-06-2025
- GLRE 05-07-2025
- Dividend Yield
- COGT N/A
- GLRE N/A
- EPS Growth
- COGT N/A
- GLRE N/A
- EPS
- COGT N/A
- GLRE 1.32
- Revenue
- COGT N/A
- GLRE $717,617,000.00
- Revenue This Year
- COGT N/A
- GLRE N/A
- Revenue Next Year
- COGT N/A
- GLRE N/A
- P/E Ratio
- COGT N/A
- GLRE $10.97
- Revenue Growth
- COGT N/A
- GLRE 2.79
- 52 Week Low
- COGT $3.72
- GLRE $11.95
- 52 Week High
- COGT $12.61
- GLRE $15.82
- Technical
- Relative Strength Index (RSI)
- COGT 56.27
- GLRE 71.34
- Support Level
- COGT $4.80
- GLRE $13.33
- Resistance Level
- COGT $4.99
- GLRE $14.65
- Average True Range (ATR)
- COGT 0.31
- GLRE 0.48
- MACD
- COGT 0.07
- GLRE 0.10
- Stochastic Oscillator
- COGT 88.56
- GLRE 86.36
About COGT Cogent Biosciences Inc.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
About GLRE Greenlight Capital Re Ltd.
Greenlight Capital Re Ltd offers property and casualty reinsurance. Its customers are property and casualty insurers, and Greenlight takes on some of their risk in exchange for insurance premiums. It operates through one operating segment: property and casualty reinsurance. It generates revenue through premiums from reinsurance on property and casualty business assumed and income from investments.